eMedicine Specialties > Infectious Diseases > HEENT Infections

Pharyngitis, Viral: Follow-up

Author: KoKo Aung, MD, MPH, FACP, Associate Professor, Department of Medicine, University of Texas Health Science Center; Adjunct Assistant Professor of Public Health, University of Texas School of Public Health
Coauthor(s): Ambrish Ojha, MD, Staff Physician, Department of Internal Medicine, Texas Tech University Health Sciences Center; Carson Lo, MD, Staff Physician, Department of Medicine, Memorial Hermann Southwest Hospital
Contributor Information and Disclosures

Updated: Jan 20, 2009

Follow-up

Deterrence/Prevention

  • Washing hands frequently, using disposable tissues, and limiting human contact are important preventive measures for the common cold syndrome and other viral pharyngitis. No consistent benefit was demonstrated in preventing a common cold with large doses of vitamin C.
  • Live adenovirus vaccines have been successfully used in military populations but are not available for civilian use.
  • Administration of influenza vaccine to high-risk individuals and those who want to prevent influenza is the major preventive measure. Amantadine may be used to prevent influenza A during outbreaks.

Complications

  • The complication rate of viral pharyngitis associated with a common cold is quite low. Purulent bacterial otitis media and sinusitis may occur.
  • Infectious mononucleosis may be complicated by tonsillar and peritonsillar abscess, necrotic epiglottitis, airway obstruction, hepatic dysfunction, splenic rupture, hypersplenism, encephalitis, pneumonitis, pericarditis, and hematologic disorders.
  • Herpetic pharyngitis may lead to necrotizing tonsillitis, epiglottitis, and recurrent disease.
  • Influenza may be complicated by secondary bacterial pneumonia. Pneumococcal pneumonia is most common. Staphylococcal pneumonia is most serious.
  • RSV infection, particularly in infants, elderly persons, and patients with underlying COPD, may be complicated by pneumonia and respiratory failure.
  • Complications of HIV infection are beyond the scope of this article. For more information, see the eMedicine article HIV Disease.

Prognosis

  • The prognosis of a patient with a common cold is excellent. Most adults recover in less than a week, and most children in less than 2 weeks.
  • In patients with infectious mononucleosis, fever disappears in approximately 10 days. Lymphadenopathy and splenomegaly disappear in approximately 4 weeks. Debility sometimes remains for approximately 2-3 months, and the condition is occasionally fatal because of splenic rupture, hypersplenism, or encephalitis.
  • The duration of uncomplicated influenza is 1-7 days. Prognosis is excellent. Most fatalities are due to secondary bacterial pneumonia.
  • Enteroviral pharyngitis is usually benign and self-limited.

Patient Education

  • Patient education should emphasize the natural course of viral infection and that it takes several days to feel better. Patients must understand that antibiotics are not needed for sore throats of viral origin. Risk of allergic reactions, fungal superinfection, and bacterial resistance should be discussed.
  • Patients should be reassured that certain measures, including pain relievers, throat sprays or lozenges, and gargling with warm salt water, improve symptoms without antibiotics. It is often challenging to reassure that antibiotic therapy is unnecessary.2
  • Fever persisting for more than 5 days, extreme throat pain causing dysphagia, inability to open the mouth wide, or fainting spells when standing should prompt a visit to a doctor.
  • For excellent patient education resources, visit eMedicine's Cold and Flu Center, Bacterial and Viral Infections Center and Ear, Nose, and Throat Center. Also, see eMedicine's patient education articles Colds, Sore Throat, Mononucleosis, and Tonsillitis.

Miscellaneous

Medicolegal Pitfalls

  • The major role of the clinician in evaluating viral pharyngitis is to distinguish pharyngitis caused by different viruses from that caused by group A beta hemolytic streptococcus (GABHS) because the latter may lead to serious sequelae such as rheumatic fever and poststreptococcal glomerulonephritis.
  • Differentiating streptococcal from viral pharyngitis is important because of the response of streptococcal infection to penicillin therapy and the ineffectiveness of antibiotic therapy in the viral infections.
  • Absence of fever or the presence of clinical features, such as conjunctivitis, cough, hoarseness, coryza, anterior stomatitis, discrete ulcerative lesions, viral exanthem, and diarrhea, strongly suggests a viral rather than streptococcal etiology.
  • A systematic review that examined the precision and accuracy of the clinical examination in diagnosing streptococcal pharyngitis found that the most useful findings for evaluating the likelihood of streptococcal pharyngitis included the presence of tonsillar exudate, pharyngeal exudate, or exposure to strep throat infection in the previous 2 weeks (positive likelihood ratios, 3.4, 2.1, and 1.9, respectively) and the absence of tender anterior cervical nodes, tonsillar enlargement, or exudate (negative likelihood ratios, 0.60, 0.63, and 0.74, respectively).8
  • Although a throat swab is commonly recommended to confirm or exclude streptococcal pharyngitis, the test's sensitivity and specificity are somewhat low (26-30% and 73-80%, respectively) compared to the criterion standard of a rise in antistreptolysin O titer. The high asymptomatic carrier rate of GABHS is probably responsible for the low predictive value of throat swabs. The rapid antigen detection test (RADT) is even less sensitive than throat cultures.
  • The rationale behind treating people with pharyngitis with antibiotics is to reduce the symptoms and the likelihood of developing complications if the condition is streptococcal in etiology. Conversely, prescribing antibiotics to everyone has some disadvantages, including, but not limited to, adverse effects of antibiotics, direct costs of antibiotics, and the impact on bacterial resistance.
  • Unnecessary antibiotic therapy for viral pharyngitis can lead to medicalization of a self-limiting illness, resulting in increasing reattendance for future episodes of this condition.9
  • Practice guidelines from the Infectious Disease Society of America (IDSA) and Standing Medical Advisory Committee of United Kingdom recommend prescribing antibiotics in patients in whom GABHS has been identified. Unfortunately, no satisfactory diagnostic test is available that can identify such patients in a timely manner.
  • Earlier scoring systems attempting to identify the streptococcal infection among patients presenting with pharyngitis correlated poorly with microbiological data. In Canada, a sore throat score based on clinical symptoms and signs for identification of streptococcal infection has been developed and validated in children and adults.10 An explicit clinical score approach to the management of patients with pharyngitis could substantially reduce unnecessary prescribing of antibiotics for viral pharyngitis.
  • A multicriteria decision analysis using the Analytic Hierarchy Process (AHP) was recently conducted to help clinicians better understand the differences between the conflicting guidelines on initial approach in a patient with pharyngitis.11 The AHP is one of several multicriteria decision-analysis methods designed to help people make better decisions in complex situations that involve tradeoffs between the advantages and disadvantages of several alternatives. The results of the AHP analysis suggest that decisions about management of adults with sore throat should incorporate both clinical estimates of the likelihood of a group A streptococcal infection and the priorities assigned to pertinent decision criteria by those affected by the decision. Additional research, however, is needed to establish the criteria to define quality management of adults who present with pharyngitis.
 


More on Pharyngitis, Viral

Overview: Pharyngitis, Viral
Differential Diagnoses & Workup: Pharyngitis, Viral
Treatment & Medication: Pharyngitis, Viral
Follow-up: Pharyngitis, Viral
References

References

  1. Perkins A. An approach to diagnosing the acute sore throat. Am Fam Physician. Jan 1997;55(1):131-8, 141-2. [Medline].

  2. Bisno AL. Acute pharyngitis. N Engl J Med. Jan 18 2001;344(3):205-11. [Medline].

  3. Weckx LL, Ruiz JE, Duperly J, et al. Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac. J Int Med Res. Mar-Apr 2002;30(2):185-94. [Medline].

  4. Graham A, Fahey T. Evidence based case report. Sore throat: diagnostic and therapeutic dilemmas. BMJ. Jul 17 1999;319(7203):173-4. [Medline].

  5. Rimantadine for prevention and treatment of influenza. Med Lett Drugs Ther. Nov 26 1993;35(910):109-10. [Medline].

  6. Two neuraminidase inhibitors for treatment of influenza. Med Lett Drugs Ther. Oct 8 1999;41(1063):91-3. [Medline].

  7. Additional Considerations to the Interim Recommendations for the Use of Influenza Antiviral Medications in the Setting of Oseltamivir Resistance among Circulating Influenza A (H1N1) Viruses, 2008-09 Influenza Season. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/flu/professionals/antivirals/additional_considerations.htm. Accessed 12/25/2008.

  8. Ebell MH, Smith MA, Barry HC, et al. The rational clinical examination. Does this patient have strep throat?. JAMA. Dec 13 2000;284(22):2912-8. [Medline].

  9. Little P, Gould C, Williamson I, Warner G, Gantley M, Kinmonth AL. Reattendance and complications in a randomised trial of prescribing strategies for sore throat: the medicalising effect of prescribing antibiotics. BMJ. Aug 9 1997;315(7104):350-2. [Medline].

  10. McIsaac WJ, White D, Tannenbaum D, et al. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. Jan 13 1998;158(1):75-83. [Medline].

  11. Singh S, Dolan JG, Centor RM. Optimal management of adults with pharyngitis--a multi-criteria decision analysis. BMC Med Inform Decis Mak. Mar 13 2006;6:14. [Medline].

  12. Cunha BA. Group A streptococcal pharyngitis. Emerg Med. 1990;22:93-96.

  13. Cunha BA. Group A streptococcal pharyngitis versus colonization. Intern Med. 1994;15:18-19.

  14. Cunha BA. The Sore Throat: Mycoplasma pneumoniae pharyngitis. Emerg Med. 1988;20:245-252.

  15. Gwaltney JM Jr, Bisno AL. Pharyngitis. In: Mandell GI, Bennett JE, Dolin R, eds. Mandell, Douglas & Bennett's Principles of Infectious Diseases. Vol 1. Churchill Livingstone; 2000:656-62.

  16. Huovinen P, Lahtonen R, Ziegler T, et al. Pharyngitis in adults: the presence and coexistence of viruses and bacterial organisms. Ann Intern Med. Apr 15 1989;110(8):612-6. [Medline].

  17. McIsaac WJ, Goel V, Slaughter PM. Reconsidering sore throats. Part 2: Alternative approach and practical office tool. Can Fam Physician. Mar 1997;43:495-500. [Medline].

  18. McIsaac WJ, Goel V, Slaughter PM, et al. Reconsidering sore throats. Part I: Problems with current clinical practice. Can Fam Physician. Mar 1997;43:485-93. [Medline].

  19. Paradise JL. Etiology and management of pharyngitis and pharyngotonsillitis in children: a current review. Ann Otol Rhinol Laryngol Suppl. Jan 1992;155:51-7. [Medline].

  20. Pichichero ME. Sore throat after sore throat after sore throat. Are you asking the critical questions?. Postgrad Med. Jan 1997;101(1):205-6, 209-12, 215-8, passim. [Medline].

  21. Wolter JM. Management of a sore throat. Antibiotics are no longer appropriate. Aust Fam Physician. Apr 1998;27(4):279-81. [Medline].

  22. Yoda K, Sata T, Kurata T, et al. Oropharyngotonsillitis associated with nonprimary Epstein-Barr virus infection. Arch Otolaryngol Head Neck Surg. Feb 2000;126(2):185-93. [Medline].

Further Reading

Keywords

viral pharyngitis, sore throat, acute pharyngitis, rhinoviral pharyngitis, adenoviral pharyngitis, EBV pharyngitis, HSV pharyngitis, influenzal pharyngitis, parainfluenzal pharyngitis, coronaviral pharyngitis, enteroviral pharyngitis, echoviral pharyngitis, RSV pharyngitis, CMV pharyngitis, cytomegaloviral pharyngitis, common cold, flu, influenza, pharynx, tonsils, upper respiratory tract infection, URTI, rhinovirus, adenovirus, Epstein-Barr virus, EBV, herpes simplex virus, HSV, parainfluenza virus, coronavirus, enterovirus, respiratory syncytial virus, RSV, cytomegalovirus, CMV, human immunodeficiency virus, HIV, coxsackievirus, echovirus, acute retroviral syndrome, infectious mononucleosis, IM, group A beta hemolytic streptococcus, GABHS

Contributor Information and Disclosures

Author

KoKo Aung, MD, MPH, FACP, Associate Professor, Department of Medicine, University of Texas Health Science Center; Adjunct Assistant Professor of Public Health, University of Texas School of Public Health
KoKo Aung, MD, MPH, FACP is a member of the following medical societies: American College of Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Ambrish Ojha, MD, Staff Physician, Department of Internal Medicine, Texas Tech University Health Sciences Center
Ambrish Ojha, MD is a member of the following medical societies: American College of Physicians and American Medical Association
Disclosure: Nothing to disclose.

Carson Lo, MD, Staff Physician, Department of Medicine, Memorial Hermann Southwest Hospital
Carson Lo, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Texas Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Gregory William Rutecki, MD, Associate Professor, Program Director, Department of Internal Medicine, Feinberg School of Medicine, Northwestern University
Gregory William Rutecki, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Nephrology, National Kidney Foundation, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Gordon L Woods, MD, Consulting Staff, Department of Internal Medicine, University Medical Center
Gordon L Woods, MD is a member of the following medical societies: Society of General Internal Medicine
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.